

Friday-Saturday, May 13-14, 2016

Memorial Sloan Kettering Symposium on Lymphoma

State of the art in biology, therapy, and patient care

CONFERENCE LOCATION

MEMORIAL SLOAN KETTERING CANCER CENTER
ZUCKERMAN RESEARCH CENTER

NFW YORK

To register or for more information, please go to:

www.mskcc.org/lymphoma2016

Memorial Sloan Kettering Symposium on Lymphoma Friday-Saturday, May 13-14, 2016

State of the art in biology, therapy, and patient care

You won't want to miss this unprecedented symposium focused on the future of Lymphoma with many of the world's leading experts.

TARGET AUDIENCE

Medical and radiation oncologists, hematopathologists, scientists, and medical trainees involved in diagnosis, treatment, and biomedical research of lymphoma.

COURSE OVERVIEW

This symposium will feature updated information on lymphoma biology, diagnosis, immunology, and genetics, and ongoing efforts to translate the scientific discoveries into novel treatment strategies for a variety of lymphomas. Faculty will review the current standard of care and present their own perspectives on how they treat various types of lymphomas. Participants will have the opportunity to discuss diagnostic and management cases, and how to incorporate biologic and genetic biomarkers into clinical practice and clinical trials.





SYMPOSIUM CHAIR

Anas Younes MD
Chief, Lymphoma Service



ORGANIZING COMMITTEE

Ahmet Dogan MD PhD



Craig Moskowitz MD



Hans Guido Wendel MD



Joachim Yahalom MD FACR



Andrew Zelenetz MD PhD



www.mskcc.org/lymphoma2016

Memorial Sloan Kettering Symposium on Lymphoma

Friday-Saturday, May 13-14, 2016

State of the art in biology, therapy, and patient care

MSK FACULTY

Maria Arcila MD

Connie Batlevi MD PhD

John F. Gerecitano MD PhD

Paul Hamlin MD

Steven Horwitz MD

Andrew M. Intlekofer MD PhD

Anita Kumar MD

Matthew Matasar MD

Alison Moskowitz MD

Ariela Noy MD

M. Lia Palomba MD

Carol Portlock MD

Mikhail Roshal MD

Michel Sadelain MD PhD

David Straus MD

Jedd D. Wolchok MD PhD

MSK conducts one of the largest clinical research programs in the world, aimed at improving the prevention, diagnosis, and treatment of cancer. In December 2013, our physicians were leading 1,259 clinical research studies for pediatric and adult cancers.

GUEST FACULTY

Ranjana Advani MD Stanford University

Steve Ansell MD PhDMayo Clinic

Francesco D'Amore MD
Aarhus University

Riccardo Dalla-Favera MD
Columbia University

Martin Dreyling MD
Ludwig Maximilian University

Randy Gascoyne MD BC Cancer Agency

Elaine Jaffe MD
National Cancer Institute

Ronald Levy MD Stanford University

Barbara Pro MD
Northwestern University

John Radford MD
University of Manchester

Louis Staudt MD PhD National Cancer Institute

Gilles Salles MD PhD Hospices Civils de Lyon

Wyndham Wilson MD PhD
National Cancer Institute

Thomas Witzig MD Mayo Clinic



Friday, May 13

7:00-8:00am BREAKFAST & REGISTRATION

8:00-8:05am Welcoming Remarks and Introduction to the

MSK Lymphoma Symposium and Grand Rounds Lecture

Anas Younes MD

8:05-8:50am **DEPARTMENT OF MEDICINE GRAND ROUNDS**

Advances in Immunotherapy of Lymphoma

Ronald Levy MD

INTRODUCTION

CHAIRS Anas Younes MD and **Elaine Jaffe MD**

9:15-9:45am Lymphoma Classification

Elaine Jaffe MD

9:45-10:15am Advances in Molecular Diagnostics

Maria Arcila MD

10:15-10:35am Advances in Radiation Oncology

Joachim Yahalom MD FACR

10:35-10:50am Survivorship Program for Patients with Lymphoma

Matthew Matasar MD

10:50-11:30am State of The Lymphoma at MSK

Anas Younes MD

11:30am-12:30pm LUNCH

DIFFUSE LARGE B CELL LYMPHOMA-I

CHAIRS Louis Staudt MD PhD and **Thomas Witzig MD**

12:30-12:45pm DLBCL Overview

Thomas Witzig MD

12:45-1:15pm Advances in DLBCL Biology

Riccardo Dalla-Favera MD

1:15-1:45pm Mechanism-Based Therapy of Lymphoma

Louis Staudt MD PhD

1:45-2:05pm Application of Genome Sequencing in Hematopathology

Practice

Ahmet Dogan MD PhD

2:05-2:20pm How I Treat DLBCL

Andrew Zelenetz MD PhD

2:20-2:35pm How I Treat Double Hit Lymphoma

Wyndham Wilson MD PhD

2:35-2:50pm How I Treat Burkitt Lymphoma

Ariela Noy MD

2:50-3:15pm CLINICAL CASES

CHAIRS Witzig, Zelenetz, Wilson, Hamlin, Noy, Jaffe

3:15-3:30pm BREAK



Memorial Sloan Kettering Symposium on Lymphoma

Friday-Saturday, May 13-14, 2016

State of the art in biology, therapy, and patient care

Friday, May 13

HODGKIN LYMPHOMA

CHAIRS John Radford MD and **Craig Moskowitz MD**

3:30-4:00pm HL Overview

John Radford MD

4:00-4:30pm Advances in HL Biology

Randy Gascoyne MD

4:30-4:45pm HL Genetics

Mikhail Roshal MD

4:45-5:00pm How I Treat Newly Diagnosed HL

David Straus MD

5:00-5:15pm How I Treat Relapsed HL

Craig Moskowitz MD

5:15-5:30pm Novel Therapy for Hodgkin Lymphoma

Alison Moskowitz MD

5:30-6:00pm CLINICAL CASES

CHAIRS Radford, Moskowitz, Younes, Ansell, Straus, Yahalom, Gascoyne

6:00-7:00pm COCKTAIL RECEPTION





Saturday, May 14

7:00-8:00am	BREAKFAST
	FOCUS ON IMMUNO ONCOLOGY CHAIRS Ronald Levy MD and Anas Younes MD
8:00-8:30am	Overview of Immune Checkpoint Inhibitors in Cancer Jedd D. Wolchok MD PhD
8:30-9:00am	Novel Immune Therapy Strategies Ronald Levy MD
9:00-9:30am	Advances in CAR T cell Therapy Michel Sadelain
9:30-9:50am	Immune Checkpoint Inhibitors in Lymphoma Steve Ansell MD PhD
9:50-10:10am	Novel Bispecific Antibodies and ADCs Ranjana Advani MD
10:10-10:30am	Novel Immune Therapy Combinations Anas Younes MD
	TRIALS IN PROGRESS CHAIRS Paul Hamlin MD and John Gerecitano MD PhD
10:30-10:40am	
10:30-10:40am 10:40-10:50am	CHAIRS Paul Hamlin MD and John Gerecitano MD PhD Trials in Progress with Immune Checkpoint Inhibitors
	CHAIRS Paul Hamlin MD and John Gerecitano MD PhD Trials in Progress with Immune Checkpoint Inhibitors A. Moskowitz, Palomba Trials in Progress with ADC
10:40-10:50am	CHAIRS Paul Hamlin MD and John Gerecitano MD PhD Trials in Progress with Immune Checkpoint Inhibitors A. Moskowitz, Palomba Trials in Progress with ADC Hamlin, Horwitz Trials in Progress with BCL2 Inhibitors
10:40-10:50am 10:50-11:00am	CHAIRS Paul Hamlin MD and John Gerecitano MD PhD Trials in Progress with Immune Checkpoint Inhibitors A. Moskowitz, Palomba Trials in Progress with ADC Hamlin, Horwitz Trials in Progress with BCL2 Inhibitors Zelenetz, Gerecitano Trials in Progress with PI3K Inhibitors
10:40-10:50am 10:50-11:00am 11:00-11:10am	CHAIRS Paul Hamlin MD and John Gerecitano MD PhD Trials in Progress with Immune Checkpoint Inhibitors A. Moskowitz, Palomba Trials in Progress with ADC Hamlin, Horwitz Trials in Progress with BCL2 Inhibitors Zelenetz, Gerecitano Trials in Progress with PI3K Inhibitors Horwitz, Gerecitano Trials with Biomarker Selection (CREBBP IDH2, EZH2,MDM2)



Saturday, May 14

T	CEI		MD	\Box	MA
	CEI	LI	MP	пυ	MA

CHAIRS F. D'Amore and S. Horwitz

11:45am-12:15pm T Cell Lymphoma Overview

Francesco D'Amore MD

12:15-12:30pm How I Treat Newly Diagnosed PTCL

Steven Horwitz MD

12:30-12:45pm How I Treat Patients with Relapsed T Cell Lymphoma

Barbara Pro MD

12:45-1:00pm CLINICAL CASES

CHAIRS Horwitz, D'Amore, Pro, Advani, Yahalom, Jaffe, Dogan

1:00-2:00pm LUNCH

MANTLE CELL AND FOLLICULAR LYMPHOMA

CHAIRS Martin Dreyling MD and Gilles Salles MD PhD

2:00-2:30pm MCL Overview

Martin Dreyling MD

2:30-3:00pm How I Treat MCL

Paul Hamlin MD

3:00-3:30pm Follicular Lymphoma Overview

Gilles Salles MD

3:30-4:00pm Insights into Follicular Lymphoma Biology

Hans Guido Wendel MD

4:00-4:30pm Epigenetic Modifiers in the Pathogenesis of

Follicular Lymphoma
Laura Pasqualucci MD

4:30-5:00pm How I Treat Newly Diagnosed Indolent Lymphoma

Carol Portlock MD

5:00-5:15pm How I Treat Waldenstrom Macroglobulinemia

M. Lia Palomba MD

5:15-5:45pm CLINICAL CASES

CHAIRS Dreyling, Salles, Portlock, Gascoyne, Dogan

5:45pm CLOSING REMARKS

Anas Younes MD



REGISTRATION

\$400	MDs, PhDs, DOs
\$280	MSK Alliance and MSK Alumni
\$200	Nurses, PAs, and other Healthcare Professionals
\$100	Residents and Fellows

Registration includes continental breakfast, lunch, and refreshment breaks. Special meals are available upon request, including vegetarian, kosher, or gluten-free. Please let us know if we can assist you with any special dietary needs.

To register, please go to:

www.mskcc.org/lymphoma2016

The registration fee is waived for all MSK staff. However, you must register for the course by visiting the Continuing Medical Education page on OneMSK

OFFICE OF CONTINUING MEDICAL EDUCATION Memorial Sloan Kettering Cancer Center 633 Third Avenue, 12th floor, New York, New York 10017 cme@mskcc.org

COURSE DESIGN

This symposium includes handson review of cases which will be intermixed with short didactic lectures. One workstation per participant.

EVALUATION

A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

ACCREDITATION STATEMENT

MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a
maximum of 17.25 AMA PRA Category
1 Credits™. Physicians should only claim
credit commensurate with the extent
of their participation in the activity. The
AMA has determined that physicians not
licensed in the United States but who
participate in this CME activity are eligible
for 17.25 AMA PRA Category 1 Credits™.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.

FACULTY DISCLOSURE

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

ACCOMMODATIONS

If you are traveling to MSK from out of town, we recommend that you reserve hotel rooms as early as possible. To make the planning a little easier, MSK has negotiated rates at select hotels in Manhattan. For a list of these hotels, please go to: www.mskcc.org/accommodations.